Cited by 940Cancer Immunotherapy and BiomarkersT-cell and B-cell ImmunologyImmunotherapy and Immune Responses

The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.

CTLA-4: new insights into its biological function and use in tumor immunotherapy

Egen, Jackson G., Kuhns, Michael S., Allison, James P.·2002·Nature Immunology

Open this paper in CoChat — free account

Abstract

The discovery of multiple costimulatory cell surface molecules that influence the course of T cell activation has increased our appreciation of the complexity of the T cell response. It remains clear, however, that CD28 and cytotoxic T lymphocyte antigen 4 (CTLA-4) are the critical costimulatory receptors that determine the early outcome of stimulation through the T cell antigen receptor (TCR). Details of how the T cell integrates TCR stimulation with the costimulatory signals of CD28 and the inhibitory signals of CTLA-4 remain to be established, but unique features of the cell biology of CTLA-4 provide important insights into its function. We summarize here recent findings that suggest a previously unrecognized role for CTLA-4 in the regulation of T cell responses. We also describe preclinical and clinical results that indicate manipulation of CTLA-4 has considerable promise as a strategy for the immunotherapy of cancer.

Integrity signals

Registry

Crossref · 10.1038/ni0702-611

Cites

93 of 93 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Self-citation
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.
Dranoff, G., Jaffee, E. M., Lazenby, A., Golumbek, P. T., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D. M., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,820
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245
Self-citation
Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
Cytotoxic T Lymphocyte–Associated Antigen 4 Plays an Essential Role in the Function of Cd25+Cd4+ Regulatory Cells That Control Intestinal Inflammation
Read, S., Malmström, V., & Powrie, F. M. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,206
B7/CD28 Costimulation Is Essential for the Homeostasis of the CD4+CD25+ Immunoregulatory T Cells that Control Autoimmune Diabetes
Salomon, B. L., Lenschow, D. J., Rhee, L., Ashourian, N., Singh, B., Sharpe, A. H., & Bluestone, J. A. (2000) · Immunity · doi:10.1016/s1074-7613(00)80195-8 · Cited by 2,058
The B7–CD28 superfamily
Sharpe, A. H., & Freeman, G. J. (2002) · Nature reviews. Immunology · doi:10.1038/nri727 · Cited by 1,759

Show all 93 references

Sorted by citations

Items 401–500 of 940

Ion channels and schizophrenia: a gene set-based analytic approach to GWAS data for biological hypothesis testing
Askland, K. D., Read, C., O’Connell, C. P., & Moore, J. H. (2011) · Human Genetics · doi:10.1007/s00439-011-1082-x · Cited by 39
Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment
Wang, S., Astsaturov, I. A., Bingham, C. A., McCarthy, K., von Mehren, M., Xu, W., Alpaugh, R. K., Tang, Y., Littlefield, B. A., Hawkins, L. D., et al. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1090-7 · Cited by 38
A SCIENCE OF THE INDIVIDUAL: Implications for a Medical School Curriculum
Childs, B., Wiener, C., & Valle, D. L. (2005) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.6.080604.162345 · Cited by 40
Innovative hydrogel-based delivery systems for immunotherapy: A review of pre-clinical progress
Mamidi, N., Poellmann, M. J., Javius-Jones, K., Nam, K., & Hong, S. (2024) · Nano Research · doi:10.1007/s12274-024-6980-z · Cited by 39
CTLA-4 on alloreactive CD4 T cells interacts with recipient CD80/86 to promote tolerance
Kurtz, J. M., Raval, F., Vallot, C., Der, J., & Sykes, M. (2009) · Blood · doi:10.1182/blood-2008-01-133736 · Cited by 37
The functional cytotoxic T lymphocyte–associated Protein 4 49G‐to‐A genetic variant and risk of pancreatic cancer
Yang, M., Sun, T., Zhou, Y., Wang, L., Liu, L., Zhang, X., Tang, X., Zhou, M., Kuang, P., Tan, W., et al. (2012) · Cancer · doi:10.1002/cncr.27455 · Cited by 37
Immune checkpoints in targeted-immunotherapy of pancreatic cancer: New hope for clinical development
Kiaie, S. H., Sanaei, M., Heshmati, M., Asadzadeh, Z., Azimi, I., Hadidi, S., Jafari, R., & Baradaran, B. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.12.011 · Cited by 37
Overcoming immunological tolerance to melanoma: targeting CTLA-4
HODI, F. S. (2010) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/j.1743-7563.2010.01271.x · Cited by 36
CTLA-4: As an Immunosuppressive Immune Checkpoint in Breast Cancer
Dehbokri, S. G., Alizadeh, N., Isazadeh, A., Baghbanzadeh, A., Abbaspour‐Ravasjani, S., Hajiasgharzadeh, K., & Baradaran, B. (2022) · Current Molecular Medicine · doi:10.2174/1566524022666220610094716 · Cited by 36
Current Experience With CTLA4-blocking Monoclonal Antibodies for the Treatment of Solid Tumors
Agarwala, S. S., & Ribas, A. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181dcd260 · Cited by 36
A Comparative Perspective on Wnt/β-Catenin Signalling in Cell Fate Determination
Garcin, C. L., & Habib, S. J. (2017) · Results and problems in cell differentiation · doi:10.1007/978-3-319-53150-2_15 · Cited by 40
Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer
Vathiotis, I. A., Moutafi, M. K., Divakar, P., Aung, T. N., Qing, T., Fernandez, A., Yaghoobi, V., El-Abed, S., Wang, Y., Guillaume, S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2103 · Cited by 36
Cell Surface Delivery of TRAIL Strongly Augments the Tumoricidal Activity of T Cells
de Bruyn, M., Wei, Y., Wiersma, V. R., Samplonius, D. F., Klip, H. G., van der Zee, A. G. J., Yang, B., Helfrich, W., & Bremer, E. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0303 · Cited by 36
Immune checkpoint inhibitors in infectious disease
King, H. A. D., & Lewin, S. R. (2024) · Immunological Reviews · doi:10.1111/imr.13388 · Cited by 35
Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer
Madan, R. A., & Gulley, J. L. (2011) · Expert Review of Vaccines · doi:10.1586/erv.10.173 · Cited by 35
Polymorphisms in genes of interleukin 12 and its receptors and their association with protection against severe malarial anaemia in children in western Kenya
Zhang, L., Prather, D. M., Eng, J. V., Crawford, S. B., Kariuki, S., ter Kuile, F. O., Terlouw, D. J., Nahlen, B. L., Lal, A. A., Slutsker, L., et al. (2010) · Malaria Journal · doi:10.1186/1475-2875-9-87 · Cited by 35
Novel immunotherapeutic approaches for hepatocellular carcinoma treatment
Busato, D., Mossenta, M., Baboçi, L., Cintio, F. D., Toffoli, G., & Bo, M. D. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1598859 · Cited by 36
The role and therapeutic implications of T cells in cancer of the lung
Neeve, S. A., Robinson, B. W. S., & Fear, V. S. (2019) · Clinical & Translational Immunology · doi:10.1002/cti2.1076 · Cited by 38
Recent advances and challenges of immune checkpoint inhibitors in immunotherapy of non-small cell lung cancer
Wu, Z., Man, S., Sun, R., Li, Z., Wu, Y., & Zuo, D. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106613 · Cited by 35
Dynamic host immunity and PD-L1/PD-1 blockade efficacy: developments after “IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer”
Abiko, K., Hamanishi, J., Matsumura, N., & Mandai, M. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01960-x · Cited by 35
DC-HIL-Expressing Myelomonocytic Cells Are Critical Promoters of Melanoma Growth
Chung, J., Tamura, K., Cruz, P. D., & Ariizumi, K. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.254 · Cited by 35
Potentiation of therapeutic immune responses against malignancies with monoclonal antibodies.
Murillo, O., Arina, A., Tirapu, I., Alfaro, C., Mazzolini, G. D., Palencia, B., de Cerio, A. L.-D., Prìeto, J., Bendandi, M., & Melero, I. (2003) · PubMed · Cited by 35
Conversion of CTLA-4 from Inhibitor to Activator of T Cells with a Bispecific Tandem Single-Chain Fv Ligand
Madrenas, J., Chau, L. A., Teft, W. A., Wu, P. W., Jussif, J. M., Kasaian, M. T., Carreno, B. M., & Ling, V. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.10.5948 · Cited by 35
From Genes to Numbers: Effective Population Sizes in Human Evolution
Hawks, J. D. (2008) · Springer eBooks · doi:10.1007/978-1-4020-6424-1_1 · Cited by 34
Current state of immune checkpoints therapy for glioblastoma
Wang, H., Yang, J., Li, X., & Hai, Z. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24729 · Cited by 36
Variable number of tandem repeat polymorphisms of the interleukin-1 receptor antagonist gene IL-1RN: a novel association with the athlete status
Cauci, S., Santolo, M. D., Ryckman, K. K., Williams, S. M., & Banfi, G. (2010) · BMC Medical Genetics · doi:10.1186/1471-2350-11-29 · Cited by 35
Combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma—safety and efficacy in a phase II study
Weide, B., Martens, A., Wistuba‐Hamprecht, K., Zelba, H., Maier, L., Lipp, H., Klumpp, B. D., Soffel, D., Eigentler, T., & Garbe, C. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1944-0 · Cited by 34
Immune mechanisms of idiosyncratic drug-induced liver injury
Mak, A., & Uetrecht, J. (2017) · Journal of Clinical and Translational Research · doi:10.18053/jctres.03.2017s1.001 · Cited by 34
The combined activation of positive costimulatory signals with modulation of a negative costimulatory signal for the enhancement of vaccine-mediated T-cell responses
Chakraborty, M., Schlom, J., & Hodge, J. W. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0291-6 · Cited by 33
Exploring Reovirus Plasticity for Improving Its Use as Oncolytic Virus
Kemp, V., Hoeben, R. C., & van den Wollenberg, D. J. M. (2015) · Viruses · doi:10.3390/v8010004 · Cited by 33
Blocking the PD-1/PD-L1 axis in advanced prostate cancer: are we moving in the right direction?
Fay, A. P., & Antonarakis, E. S. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.01.37 · Cited by 33
Ipilimumab and Its Derived EGFR Aptamer-Based Conjugate Induce Efficient NK Cell Activation against Cancer Cells
Passariello, M., Camorani, S., Vetrei, C., Ricci, S., Cerchia, L., & Lorenzo, C. D. (2020) · Cancers · doi:10.3390/cancers12020331 · Cited by 33
Nivolumab plus ipilimumab combination therapy in cancer: Current evidence to date
Nikoo, M., Rabiee, F., Mohebbi, H., Eghbalifard, N., Rajabi, H., Yazdani, Y., Sakhaei, D., Khosravifarsani, M., & Akhavan‐Sigari, R. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.109881 · Cited by 33
Novel therapies targeting the immune system: CTLA4 blockade with tremelimumab (CP-675,206), a fully human monoclonal antibody
Camacho, L. H. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.3.371 · Cited by 33
Emerging mechanisms of immune regulation: the extended B7 family and regulatory T cells.
Loke, P., & Allison, J. P. (2004) · Arthritis Research · doi:10.1186/ar1225 · Cited by 34
Self-citation
Mathematical Models and Immune Cell Biology
Molina-Parı́s, C., & Lythe, G. (2011) · Springer eBooks · doi:10.1007/978-1-4419-7725-0 · Cited by 34
Vaccination with minigenes encoding for novel ‘self’ antigens are effective in DNA-vaccination against neuroblastoma
Huebener, N., Lange, B., Lemmel, C., Rammensee, H., Strandsby, A., Wenkel, J., Jikai, J., Zeng, Y., Gaedicke, G., & Lode, H. N. (2003) · Cancer Letters · doi:10.1016/s0304-3835(03)00102-2 · Cited by 33
Emerging therapies for melanoma
Katipamula, R., & Markovic, S. N. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.4.553 · Cited by 33
Erratum to: Inter-ethnic differences in genetic variants within the transmembrane protease, serine 6 (TMPRSS6) gene associated with iron status indicators: a systematic review with meta-analyses
Gichohi‐Wainaina, W. N., Towers, G. W., Swinkels, D. W., Zimmermann, M. B., Feskens, E. J. M., & Melse‐Boonstra, A. (2015) · Genes & Nutrition · doi:10.1007/s12263-015-0457-3 · Cited by 33
Cancer Vaccines in Phase II/III Clinical Trials: State of the Art and Future Perspectives
Cecco, S., Muraro, E., Giacomin, E., Martorelli, D., Lazzarini, R., Baldo, P., & Dolcetti, R. (2010) · Current Cancer Drug Targets · doi:10.2174/156800911793743664 · Cited by 35
Allele and haplotype diversity of X-chromosomal STRs in Ivory Coast
Pasino, S., Caratti, S., Pero, M. D., Santovito, A., Torre, C., & Robino, C. (2011) · International Journal of Legal Medicine · doi:10.1007/s00414-011-0591-4 · Cited by 32
Hepatitis B e-antigen Persistency is Associated with the Properties of HBV-Specific CD8 T Cells in CHB Patients
Peng, G., Luo, B., Li, J., Zhao, D., Wu, W., Chen, F., & Chen, Z. (2010) · Journal of Clinical Immunology · doi:10.1007/s10875-010-9483-5 · Cited by 32
Physiologic regulation of central and peripheral T cell tolerance: lessons for therapeutic applications
Li, L., & Boussiotis, V. A. (2006) · Journal of Molecular Medicine · doi:10.1007/s00109-006-0098-5 · Cited by 32
Leukemic B Cell CTLA-4 Suppresses Costimulation of T Cells
Do, P., Beckwith, K. A., Cheney, C. M., Tran, M., Beaver, L. P., Griffin, B. G., Mo, X. M., Liu, Y., Lapalombella, R., Hertlein, E. K., et al. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1801359 · Cited by 33
Innovative Medicine
Nakao, K., Minato, N., & Üemoto, S. (2015) · Springer eBooks · doi:10.1007/978-4-431-55651-0 · Cited by 34
Positive and negative consequences of Fas/Fas ligand interactions in the antitumor response
Scott, I. (2005) · Frontiers in bioscience · doi:10.2741/1575 · Cited by 32
CTLA-4: Negative Regulator of the Immune Response and a Target for Cancer Therapy
Keilholz, U. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318174a4fe · Cited by 32
Cytotoxic T-Lymphocyte Antigen-4 and Programmed Death-1 Function as Negative Regulators of Lymphocyte Activation
Carter, L., & Carreno, B. M. (2003) · Immunologic Research · doi:10.1385/ir:28:1:49 · Cited by 32
CD152 (CTLA‐4) regulates effector functions of CD8+ T lymphocytes by repressing Eomesodermin
Hegel, J. K., Knieke, K., Kolar, P., Reiner, S. L., & Brunner-Weinzierl, M. C. (2009) · European Journal of Immunology · doi:10.1002/eji.200838770 · Cited by 32
CTLA-4 Engagement Acts as a Brake on CD4+ T Cell Proliferation and Cytokine Production but Is Not Required for Tuning T Cell Reactivity in Adaptive Tolerance
Inobe, M., & Schwartz, R. H. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.12.7239 · Cited by 32
The effect of organ-specific tumor microenvironments on response patterns to immunotherapy
Conway, J. W., Braden, J., Wilmott, J. S., Scolyer, R. A., Long, G. V., & da Silva, I. P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1030147 · Cited by 32
Immune Checkpoint Blockade in Breast Cancer Therapy
Bu, X., Yao, Y., & Li, X. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-6020-5_18 · Cited by 31
Therapeutic Cancer Vaccines
Bilušić, M., & Madan, R. A. (2011) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3182068cdb · Cited by 31
Tumor immunity via homeostatic T cell proliferation: mechanistic aspects and clinical perspectives
Baccalà, R., González‐Quintial, R., Dummer, W., & Theofilopoulos, A. N. (2005) · Springer Seminars in Immunopathology · doi:10.1007/s00281-004-0196-9 · Cited by 31
A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance
Santiago-Sánchez, G. S., Fabian, K. P., & Hodge, J. W. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2308097 · Cited by 31
Non‐ HLA genomics: does it have a role in predicting haematopoietic stem cell transplantation outcome?
Dickinson, A. M., & Norden, J. (2015) · International Journal of Immunogenetics · doi:10.1111/iji.12202 · Cited by 30
Sequential treatment with immunotherapy and BRAF inhibitors in BRAF-mutant advanced melanoma
Aya, F., Fernández-Martínez, A., Gaba, L., Victoria, I., Tosca, M., Pineda, E., Gascón, P., Prat, A., & Arance, A. M. (2016) · Clinical & Translational Oncology · doi:10.1007/s12094-016-1514-0 · Cited by 30
Cytokine Therapy for Cancer
Kim‐Schulze, S., Taback, B., & Kaufman, H. L. (2007) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2007.07.011 · Cited by 30
Regulatory T Cells in Colorectal Cancer: From Biology to Prognostic Relevance
Mougiakakos, D. (2011) · Cancers · doi:10.3390/cancers3021708 · Cited by 30
Keeping DCs awake by putting SOCS1 to sleep
Kobayashi, T., & Yoshimura, A. (2005) · Trends in Immunology · doi:10.1016/j.it.2005.02.004 · Cited by 30
Induction of Adaptive Anti-HER2/neu Immune Responses in a Phase 1B/2 Trial of 2B1 Bispecific Murine Monoclonal Antibody in Metastatic Breast Cancer (E3194): A Trial Coordinated by the Eastern Cooperative Oncology Group
Borghaei, H., Alpaugh, R. K., Bernardo, P., de Palazzo, I. G., Dutcher, J. P., Venkatraj, U., Wood, W. C., Goldstein, L. J., & Weiner, L. M. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31803bb421 · Cited by 31
Therapeutic vaccination with tumor cells that engage CD137
Hellström, K. E., & Hellström, I. (2003) · Journal of Molecular Medicine · doi:10.1007/s00109-002-0413-8 · Cited by 30
Cancer‐Associated Fibroblasts: Heterogeneity, Cancer Pathogenesis, and Therapeutic Targets
Li, Y., Liu, Q., Jing, X., Wang, Y., Jia, X., Yang, X., & Chen, K. (2025) · MedComm · doi:10.1002/mco2.70292 · Cited by 32
Nivolumab + Ipilimumab for patients with hepatocellular carcinoma previously treated with Sorafenib
Tsang, J., Wong, J. S. L., Kwok, G. W., Li, B. C. W., Leung, R. C.-Y., Chiu, J. W. Y., Cheung, T. T., & Yau, T. C. C. (2021) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1899808 · Cited by 29
Association between CTLA-4 60G/A and -1661A/G Polymorphisms and the Risk of Cancers: A Meta-Analysis
Yan, Q., Chen, P., Lu, A., Zhao, P., & Gu, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083710 · Cited by 28
Comparison of Metabolic and Morphological Response Criteria for Early Prediction of Response and Survival in NSCLC Patients Treated With Anti-PD-1/PD-L1
Castello, A., Rossi, S., Toschi, L., & Lopci, E. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01090 · Cited by 28
Management of Endocrine and Metabolic Toxicities of Immune-Checkpoint Inhibitors: From Clinical Studies to a Real-Life Scenario
Spagnolo, C. C., Giuffrida, G., Cannavò, S., Franchina, T., Silvestris, N., Ruggeri, R. M., & Santarpía, M. (2022) · Cancers · doi:10.3390/cancers15010246 · Cited by 28
Analysis for genotyping Duffy blood group in inhabitants of Sudan, the Fourth Cataract of the Nile
Kempińska‐Podhorodecka, A., Knap, O., Drozd, A., Kaczmarczyk, M., Parafiniuk, M., Parczewski, M., & Ciechanowicz, A. (2012) · Malaria Journal · doi:10.1186/1475-2875-11-115 · Cited by 28
Provision of Granulocyte-Macrophage Colony-Stimulating Factor Converts an Autoimmune Response to a Self-Antigen into an Antitumor Response
Ji, Q., Gondek, D. C., & Hurwitz, A. A. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.3.1456 · Cited by 28
Immunotherapy for prostate cancer
Fong, L. H. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)00350-6 · Cited by 28
The miRNA and PD-1/PD-L1 signaling axis: an arsenal of immunotherapeutic targets against lung cancer
Yadav, R., Khatkar, R., Yap, K. C.-Y., Kang, C., Lyu, J., SINGH, R. K., Mandal, S., Mohanta, A., Lam, H. Y., Okina, E., et al. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02182-1 · Cited by 29
Innovative CAR-T Cell Therapy for Solid Tumor; Current Duel between CAR-T Spear and Tumor Shield
Jo, Y., Ali, L. A., Shim, J. A., Lee, B. H., & Hong, C. (2020) · Cancers · doi:10.3390/cancers12082087 · Cited by 28
Enhancement of Human Melanoma Antigen Expression by IFN-β
Dunn, I. S., Haggerty, T. J., Kono, M., Durda, P. J., Butera, D., Macdonald, D. B., Benson, E. M., Rose, L. B., & Kurnick, J. T. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.4.2134 · Cited by 27
Cancer immunotherapy: Progress and challenges in the clinical setting
Zarour, H. M., & Ferrone, S. (2011) · European Journal of Immunology · doi:10.1002/eji.201190035 · Cited by 27
CTLA-4 gene polymorphism at position +49 A>G in exon 1: a risk factor for cervical cancer in Indian women
Gokhale, P., Kerkar, S. C., Tongaonkar, H. B., Salvi, V. S., & Mania‐Pramanik, J. (2013) · Cancer Genetics · doi:10.1016/j.cancergen.2013.04.003 · Cited by 27
Altered regulatory T cell phenotype in latent autoimmune diabetes of the adults (LADA)
Radenkovic, M., Silver, C., Arvastsson, J., Lynch, K. F., Lernmark, Å., Harris, R. A., Agardh, C., & Cilio, C. (2016) · Clinical & Experimental Immunology · doi:10.1111/cei.12834 · Cited by 29
CD28, Costimulator or Agonist Receptor?
Margulies, D. H. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030303 · Cited by 27
Efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer
Wang, S., Hao, J., Wang, H., Fang, Y., & Tan, L. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1457600 · Cited by 26
CD4+/CD25+ Cells in Systemic Inflammation in COPD
Domagala-Kulawik, J. J., Hoser, G., Dąbrowska, M., Safianowska, A., & Chazan, R. (2010) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2010.02474.x · Cited by 26
Genetic variations in CTLA-4, TNF-α, and LTA and susceptibility to T-cell lymphoma in a Chinese population
Liu, J., Liu, J., Song, B., Wang, T., Liu, Y., Hao, J., & Yu, J. (2013) · Cancer Epidemiology · doi:10.1016/j.canep.2013.08.011 · Cited by 26
Engineering Protein Delivery Depots for Cancer Immunotherapy
Wen, D., Chen, G., Chen, Q., Li, P. Y., Cheng, H., & Gu, Z. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00061 · Cited by 26
A Cross-Species Reactive TIGIT-Blocking Antibody Fc Dependently Confers Potent Antitumor Effects
Yang, F., Zhao, L., Wei, Z., Yang, Y., Liu, J., Li, Y., Tian, X., Liu, X., Lü, X., & Sui, J. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1901413 · Cited by 26
Targeted therapies in melanoma
Queirolo, P., & Acquati, M. (2006) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2006.07.009 · Cited by 26
Detrimental role for CD4 + T lymphocytes in murine diffuse peritonitis due to inhibition of local bacterial elimination
Busse, M., Traeger, T., Pötschke, C., Billing, A. M., Dummer, A., Friebe, E., Kiank, C., Grunwald, U., Jack, R. S., Schütt, C., et al. (2007) · Gut · doi:10.1136/gut.2007.121616 · Cited by 26
Vaccination: role in metastatic melanoma
Pilla, L., Valenti, R., Marrari, A., Patuzzo, R., Santinami, M., Parmiani, G., & Rivoltini, L. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.8.1305 · Cited by 26
Immune Checkpoint Inhibitors: Recent Clinical Advances and Future Prospects
Banday, A. H., & Abdalla, M. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220819115849 · Cited by 25
Immune Therapy for Ovarian Cancer: Promise and Pitfalls
Thibodeaux, S. R., & Curiel, T. J. (2011) · International Reviews of Immunology · doi:10.3109/08830185.2011.567361 · Cited by 25
Alternatives to calcineurin inhibition in renal transplantation: belatacept, the first co-stimulation blocker
Poirier, N., Blancho, G., & Vanhove, B. (2010) · Immunotherapy · doi:10.2217/imt.10.57 · Cited by 25
HIV-related cognitive impairment shows bi-directional association with dopamine receptor DRD1 and DRD2 polymorphisms in substance-dependent and substance-independent populations
Jacobs, M. M., Murray, J., Byrd, D., Hurd, Y. L., & Morgello, S. (2013) · Journal of NeuroVirology · doi:10.1007/s13365-013-0204-8 · Cited by 25
Early Evaluation of Immunotherapy Response in Lymphoma Patients by 18F-FDG PET/CT: A Literature Overview
Ferrari, C., Maggialetti, N., Masi, T., Nappi, A. G., Santo, G., Asabella, A. N., & Rubini, G. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11030217 · Cited by 25
Immune Checkpoint Inhibitors: Review of the Existing Evidence and Challenges in Breast Cancer
Jalalvand, M., Darbeheshti, F., & Rezaei, N. (2021) · Immunotherapy · doi:10.2217/imt-2020-0283 · Cited by 26
In vivo imaging of therapy-induced anti-cancer immune responses in humans
Aarntzen, E. H. J. G., Srinivas, M., Radu, C. G., Punt, C. J. A., Boerman, O. C., Figdor, C. G., Oyen, W. J. G., & de Vries, I. J. M. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1159-2 · Cited by 26
Association between CTLA-4 genetic polymorphisms and susceptibility to osteosarcoma in Chinese Han population
He, J., Wang, J., Wang, D., Dai, S., Yv, T., Chen, P., Ma, R., Diao, C., & Lv, G. (2014) · Endocrine · doi:10.1007/s12020-013-0050-8 · Cited by 24
Polymorphic KIR3DL3 expression modulates tissue-resident and innate-like T cells
Palmer, W. H., Leaton, L. A., Codo, A. C., Crute, B. W., Roest, J., Zhu, S., Petersen, J., Tobin, R. P., Hume, P. S., Stone, M. L., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.ade5343 · Cited by 24
Combining vaccines with conventional therapies for cancer
Arlen, P. M., Madan, R. A., Hodge, J. W., Schlom, J., & Gulley, J. L. (2007) · Update on Cancer Therapeutics · doi:10.1016/j.uct.2007.04.004 · Cited by 24
Immunization with a Circumsporozoite Epitope Fused to Bordetella pertussis Adenylate Cyclase in Conjunction with Cytotoxic T-Lymphocyte-Associated Antigen 4 Blockade Confers Protection against Plasmodium berghei Liver-Stage Malaria
Tartz, S., Kamanová, J., Simsova, M., Šebo, P., Bolte, S., Heussler, V. T., Fleischer, B., & Jacobs, T. (2006) · Infection and Immunity · doi:10.1128/iai.74.4.2277-2285.2006 · Cited by 24
Racial disparities in risk factors for thrombosis
Itakura, H. (2005) · Current Opinion in Hematology · doi:10.1097/01.moh.0000167746.26145.53 · Cited by 24
Melanoma immunotherapy dominates the field
Diamantopoulos, P. T., & Gogas, H. J. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.06.32 · Cited by 25
Checkpoint blockade in solid tumors and B-cell malignancies, with special consideration of the role of CD200
Gorczynski, R. M., & Zhu, F. (2017) · Cancer Management and Research · doi:10.2147/cmar.s147326 · Cited by 24
Toward innovative combinational immunotherapy: A systems biology perspective
Li, X., Yang, J., Wu, Y.-L. L. C., & Hou, J. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.05.003 · Cited by 24

Authors: Egen, J. G., Kuhns, M. S., & Allison, J. P.
Affiliations: Howard Hughes Medical Institute (US)
Corresponding author: Allison, James P.
ORCID: Egen, Jackson G.
Kuhns, Michael S.
Allison, James P.
Venue: Nature Immunology
Publisher: Springer Science and Business Media LLC
Published: 2002-07
Volume: 3
Issue: 7
Pages: 611-618
ISSN: 1529-2908 (ISSN-L)
1529-2916
DOI: 10.1038/ni0702-611
OpenAlex: W2140460887
Cited by: 940
References: 93
Citations by year: 2026: 10 · 2025: 15 · 2024: 30 · 2023: 34 · 2022: 45 · 2021: 50 · 2020: 43 · 2019: 33 · 2018: 27 · 2017: 36 · 2016: 28 · 2015: 32 · 2014: 31 · 2013: 38 · 2012: 25
FWCI: 5.88
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature Immunology (publishedVersion)
PubMed (publishedVersion)
Funders: Howard Hughes Medical Institute
National Institutes of Health
National Cancer Institute (CA40041, R01CA057986, CA57986)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: CTLA-4, costimulatory receptors, CD28, T cell activation, T cell receptor signaling, T cell regulation, cancer immunotherapy, CTLA-4 blockade, immune checkpoint blockade
MeSH terms: Abatacept, Animals, Antigens, Differentiation, Cell Division, Colonic Neoplasms, Disease Models, Animal, Fibrosarcoma, Gene Expression Regulation, Humans, Immunotherapy, Lymphocyte Activation, Neoplasms, T-Lymphocytes, Antigens, CD, Immunoconjugates, Mice, CTLA-4 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

CTLA-4: new insights into its biological function and use in tumor immunotherapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks